we are excited about biogen over the next one to two years. of course that is around the core focus of wa kemby can be a $5, $ 6 billion drug critically important for biogen. in addition, the reality of this deal is important. a billion dollar drug given size, scope and importance what it means. >> michael, a couple questions given the carter administration, merges and acquisitions. could this run into issues secondly, if this, you saw stock reaction rare when buyer goes up. good news for the stock in the marke market who do you see then doing moshgt acquisitions in your crystal ball pharma hasn't delivered. bristol trading, pfizer down where is that going, in what areas do you see acquisitions happening? >> very good i do think what we, we're hearing this morning was some increased chatter around potential for senator warning to probably raise more concern. she has been doing that in the past certainly with the verizon and pfizer deal. both by way of knowledging $27 billion and $40 billion. we expect could be some particularly because biogen

biogen falling despite the company's alzheimer's drug getting fda approval kevin, you don't own biogenut have j&j, united health and merck. >> the more traditional pharmaceuticals are where you want to be b biotech has been a dead space. lower multiples relatively speaking we like the health care trade heading into this idea baby boomers will be utilizing it we've owned merck for a long time practically no debt and a stock you can own both for the short term and the long term j&j it looks like the tpowder lawsuit. health care may be in trouble as you head into a presidential election year. an opportunity to add to the name very solid growth but on weakness you probably want to add to >> weiss, what's your second half outlook the biotech etf down 4.5%, 5%. moderna and united health you own. >> i sort of feel like on the losing side of a roundhouse kick against unh. goldman lowered numbers. still above the street you've derisked it in front of the courts coming out next week. increased surgeries for medicare patients so i haven't sold any. i bought a little. tried to catch and it hasn't

these drugs, leqembi there from biogen, hay stop the production of the beta amyloid proteins.lonal antibodies directed at the production of these proteens. david: now, do they just slow the process of the disease, or can hay actually reverse some of the symptoms of alzheimer's? >> they slow the process. great question, as usual. over 18-month period of time, both of them studied over an 8-month -- 18-month period of time, leqembi decreased the cognitive impairment by about 27%. there's only about 1.5 million people in the united states who are early enough to actually qualify for these drugs because once you're in your late stages, it is not going to reis verse the process. so i'm -- reverse the process. i'm a little surprised that biogen is putting all their eggs in this basket, saying leqembi is going to be the lifesaver. their stock prices are down today about 5 points. david: i saw that. >> i don't know that this is the holy grail. this is not another lipitor or another viagra, this is not. this is going to to be a useful drug. here's the other rub, david, the drug -- i do

biogen has been trying to expand .se drugs are losing revenue and they haven't looking for growth and this is one of the ways they will do that is by finding the drug which analysts say will generate $1.5 billion. jon: you are constantly covering this sector and it does not every day we see this company pull the trigger on a deal. michelle: this is biogen's biggest deal by a landside and it is thanks to the ceo. he is known as a dealmaker. when they hired him in november, it was well expected deals. even set on the first earnings call he said you shouldn't have hired me if he didn't expect me to do that. this is the perfect deal because it hits all of the buckets, rare disease, neural and will help growth. jon: michelle, thanks very much. i hope you get some sleep this weekend. michelle davis covering this big multibillion-dollar deal. we continue to see the markets march higher into the weekend. s&p 4600 is the next target we are watching for and also a number of other numbers, u.s. 10 year 4%. the bloomberg dollar in

biogen reversed premarket losses to on the news. it is up just slightly, but just because biogen put the credit card down and has the funds does not mean the government will let the transaction or any merger these days go through. joining me now, rbc cap pal market -- capital markets deputy the chairman larry grapstein knows all about m&a activity. let's talk about the government breathing down these company' backs. am i right? just because they say they're going to merge, this whole thing could be thrown i off. >> yeah. we've had two major developments in the last few weeks. first we had enhanced reporting requirements for hsr which means a lot more information the companies have to provide when they file. and secondly, you know, equally and maybe more important, we had revised merger greens that were issues i -- guidelines that were issued by the ftc, the federal trade commission. liz: this government, at least this administration, is not exactly merger-friendly, you know? complete opposite. >> it's been very clear since the begin

show me biogen, please. where are we? we've got biogen down 3%.% of work force and they'll focus more resources on the rollout of the new alzheimer drug. the stock though is down 3%. fixing seattle's homeless problem got more complicated and the judge said the encampment clearing rules got more unconstitutional. jason rantz has the story next. ♪ you ok, man? the internet is telling me a million different ways i should be trading. look! what's up my trade dogs? you should be listening to me. you want to be rich like me? you want to trust me on this one. [inaudible] wow! yeah! it's time to take control of your investing education. cut through the noise with best-in-class education resources that match your preferred style of learning. learn your way. not theirs. td ameritrade. where smart investors get smarter℠. so, you have diabetes, and your glucose is heading low. [ alert sound ] dexcom g7, the most accurate cgm, can alert you before you go too low. now, that's more peace of mind with dexcom g7. ♪ ♪ what do we always say, son? liberty mutual cust

be the marginal player on the fda, "squawk" did a great job covering the approval of the drug for biogen responding well today. >> it was kind of handicapped for, you know, a while beforehand, so i think a lot of it got into, you know, got into the stock. there is some talk about the way it's going to be labeled with some warnings and maybe uncertainties about exactly how much it's going to be prescribed because of that and pricing and all the rest of it so, i think a lot of the news was already in the stock and now it's about really figuring out exactly how it's going to penetrate the market once it's -- once it is out there >> isn't accessibility also a component here too if you're someone who lives in maybe a rural area or, you know, one not near somewhere that distributes this drug, it's -- what is it, twice a month that you have to get an injection there are side effects risks, logistics risks, accessibility risks, there's a waiting list, so it could be a little clunky for a while before it really becomes much more mainstream, especially as a treatment for the very, very large total

a lot of hop right now to sort of stem th growth problem i think you have to wait and see. >> the biogen shares were up b two, after cutting their forecast because of inventor issues would you get into those genes >> well, you know, after covid i would have to get into a different size of those jeans. but i think what you've seen with levi strauss reflects a lot of what happened with spending they got hit, then they ha supply chain issues coming out of covid and they had a lot of demand and the stock was coming back up and down is that demand starting to fade, and starting to go into a growth slow down at the very least. it's hard to get behind a lot of consumer discretionary names inflation, although it has com down a lot, it is stil lingering at higher levels tha we're usedto people are paying more at th grocery stores, paying more to go out for food. so things like jeans and tops, you're wearing them out a little bit more that's what levis is realizing and seeing in their numbers. >> and let's check up on where you stand with the stock draft you and your partner, diamon deshields. you

partner biogen. a study verified it's an effective treatment for patients with alzheimer's. it's been shown to slow down the disease progress by reducing sticky deposits of a protein called amyloid beta that form in the brain. the fda says it's the first such treatment to gain full approval. it received accelerated approval from the fda in january. the administration's advisory panel decided in june that the confirmatory study verified the efficacy of the drug. the agency said it should be used for patients with mild cognitive impairment or the mild dementia stage of alzheimer's. applications for approval have been filed in other parts of the world including japan, europe, and china. a group of japanese patients and supporter supporters expressed high hopes that it'll get the green light in the country. >>> twitter is threatening to sue the parent company of facebook and instagram over its new threads platform. it's accusing meta of hiring former twitter employees to create a copycat app. twitter's legal team sent a letter to meta's ceo, mark zuckerberg. it says twitter has

its dividend by 55%, but the market wanted numbers, they got numbers, that's why it's up shares of biogeny're about 2% but now 3% lower after announcing the fda approved its first alzheimer's drug, which means patients could get reimbursed for the cost, but this is the caveat doctors would have to submit patient data before the treatment as well as every six months to a registry database, so that means more paperwork analysts seem to be a little bit split on how fast biogen can ramp up the drug for production, so maybe that's adding to some of the selloff you're seeing, but still, great news for alzheimer's. >> that is for sure, kristina. thank you so much. last chance to weigh in on our twitter question we asked, what would the fed do at its next meeting? hike, cut rates, or pause? head to @cnbcclosingbell on twitter. we will bring you the results a of this break. >>> let's get the results of our twitter question we asked, what will the fed do at its next meeting? hike rates, overwhelming winner here 72% of you that about links up with the odds the markets are giving, a 25-basis-point hi

on biogen, we are buy rated. i do believe the launch is going to take time, becky.e are below consensus i think once we get past these quarters and the launch takes off we do think this will be a significant driver and significant transformation toward biogen stock and certainly for other younger companies, $4 billion in market cap, has a potent version of it in subcutaneous, making it easier for patients -- >> give yourself the shot? >> either through an auto injector or through a nurse that would be able to do it rather than sitting in a chair and having to go to an infusion center that will be a big change as well that is a potential take out target or significant upside of that >> michael, thanks for coming in >> great to be here. >> great news. >>> coming up, we're going to talk travel inflation, ai and why so many americans are heading to europe to see the sights this summer we're going to talk about all of those issues with expedia ceo peter kern in just a moment. take a look at futures right now as we head to a break. you're looking at some red arrows the na

new and exciting and will trigger a great amount of emotions amongst our patients, how houses and biogen puts in to this new concept. harold's a new era in the treatment of many to deficits in the future. some of the technology will likely be able to restore the function of the ohms and hands as well. brain implants can also use the symptoms of parkinson's. the treatment can reduce, trim is and muscle rigidity using electrical stimulation. many patients who suffer from the disease have benefits and jim sidle is conscious during the operation to implant electrodes into his brain. the surgeon needs him to respond and speak. zydeco was diagnosed with parkinson's in his mid forties. despite heavy medication, his tremors won't go away. he's hoping deep brain stimulation will help the citizens. we can see the tremors very clearly. now we're going to stimulate individual contacts the day before the procedure. the went down for a walk. he's not scared. he just longs for the tremors to stop. you can see how much i'm trembling to that i'm not shivering due to the cold. it's the tremor hunter, my h

the judge made by the department of biogen.atment of fast money yesterday. >> this treatment is safe and effective for the alzheimer's disease. this is from the clinical trial. we believe about 100,000 individuals could be diagnosed and eligible for treatment. >> biotech says there's a lot of things floating around on how to view this. compared to a drug for cancer that came and it ushered in subsequent treatments that were very powerful but maybe wasn't the end of it at the beginning. is there similarities in your view? it is a start for something nobody has had any luck with in the past. >> i think you are right on point. it's a big breakthrough for them to have a new alzheimer's drug is the first time taken gl timers patient. a big breakthrough. importantly, i think it is the start of the next decade with innovation and a lot of companies working on new treatments to approve on this in combination. at that is great for alzheimer's patient. they are on a new era here for the treatment of alzheimer's. >> that's a huge market.

biogen, job cuts. >> 1000 but workforce of 9000 so intent of the workforce.o save money but don't they have to fully approved alzheimer's drug? we've been talking about it. they have it, it's great. it's not yet profitable for the first half of this year they lost $40 million because of the expenses that go to develop me and commercializing. stuart: that can be. thanks, lauren. an anonymous democrat sounding the alarm of biden's age, calls are coming from both sides of the aisle. the view cohost, not a fan of ron desantis. watch this. >> i have been spitting mad about the cultural wars ron desantis has been creating so when he says he has nothing to do with it -- shame on you people in florida. stuart: so outraged that the audio was cut. tell you about that. white house county dynamics and does come in for criticism. i want to talk to very couple about this, low unemployment and absence of recession. i want to square that with bidenomics. larry kudlow next. ♪ in. ♪ good luck. td ameritrade, this is anna. hi anna, this position is all over the place, help! hey

biogen said the drug will not be profitable until late next year possibly 2025 and it cost more thanays june sales fell two and a half% from last year end 1.4% from last month, that's the steepest monthly decrease in over three years. they are maintaining stock at an outperform training but raise price target 255-6535 instructors at 527, a loss of 1%. blue cutting profit outlook after of steep drop in wholesale in the translation, discount could be on the way. the company did the estimates for the current quarter but stock is getting hammered, it's down almost 7%. if you do need a new parody's, he'd likely go to a local mall but don't be surprised if you come across an indoor pickle ball then you because the new export craze is taking the spot of big-box retailers. let's go to madison all worth in stamford, connecticut, one of the largest indoor pickle ball then use, you're getting good, madison. >> thank you. i've had a lot of practice which is fun. we are standing in front of the escalator that used to be part of the saks fifth avenue, that's what this was. upstairs you have signs

. >> biogen, they report next week this is the fourth cheapest stock in the whole xlb >> thank you forou watching >> well, i talked about charles schwab, 60 times next year's earnings, and all the momentum is going in the right direction. >> i think amy has a touche for jim. that has to be your goldman sachs, right >> it's mine >> it's my goldman sachs i think just as a portfolio manager, watching how it's trading, not a great quarter, i think it works from here >> jim >> there's still time to play economic strength here >> "the exchange" is now, everybody. ♪ ♪ >>> thank you very much, scott welcome to "the exchange." i'm kelly evans. here's what's ahead. one of the best real-time indicators of the economy just surprised everyone, and it's complicating the outlook for the fed and investors. we'll tell you what it is and where the market has opportunity because of it. >>> tesla and netflix, we have the trades from here with one highly potential downside of 80% and the other a 20% rally. not going to tell you which is which. stick around the analyst behind those calls are he

the treatment for alzheimer's, the food drug administration has granted full approval to drugmaker biogeniche disease rather than just treating symptoms. the trial data show the slowing of the development of the disease of 27% of patients in the earliest stages, the approval expected to include medicare coverage for adults over 65 who been unable to afford the $26000 a year drug. more than 6 million americans live with alzheimer's. another week, another company controversy, ben & jerry's parent company losing nearly $2 billion in market cap following calls to boycott the ice cream maker on july 4 the company issuing a tweet condemning the u.s. for existing on stolen indigenous lien. many critics on social media calling for a boycott of the ice cream maker, some calling about like moment, shares, what are they doing they are down. r&b singer jill scott change this words of the national anthem live on stage with anti-american lyrics. take a listen to the bazaar rendition ♪ ♪ the land of the free ♪ ♪ but the home of the slaves ♪ ♪ >> scott was performing on the second day of the festival on pe

when biogen came out with the blockbuster drug what came next was the reality of how expensive it is. >> that's exactly right. the price of the drug is one thing. what about the infusion center, the care, the screening for the test and then the imaging to ensure that the patients are safe along the way. maria: yeah. >> let me start with diagnostics. i did see the segment on the finger prick. i would say there's been tremendous advances. diagnostics will be the game changer many i think you're absolutely right to focus on this topic. the way it works, you have to find a doctor. we live in new york so it's pretty easy. in large parts of the country it's not. you have cognitive tests, lab tests, imaging. not everybody can get to a place and get a pet scan. wouldn't a finger prick make it simple? here's what i envision down the road. you go to the doctor, you have your annual miss i call. the doctor goes your cholesterol is high, have leafy green vegetables and mediterranean diet and these are the proteins in your brain we're looking at. it would be great to see at that time drugs we coul

i've watched the fortunes of biogen go up and down.on that we will stop if not prevent alzheimers? >> i'm very optimistic that we can slow it down. not just because of this discovery, that reducing plaque helps the symptoms. also we're learning a lot about lifestyle changes. the role of food in the progression of alzheimers. chronic poor sleep has been identified many people as a potential contributing factor to the development of alzheimers. it's ironic. we'll spend bills of dollars on a medication for alzheimers, but we've barely started to scratch the surface on what causes alzheimers. and those causes appear to be right in front of us in clear view. >> charles: how about medical prevention? we need to talk about that across the board. thanks, dr. marty makary. sorry to hear about your aunt. it's so painful for everybody i've talked to about it. >> thank you. >> charles: forget the battle between these two billionaires in a cage. try court. we have the latest. who did want to be george jetson flying around in the car? we may be clos

are these big premium purchases by, let's call it, big pharma in this case, not quite as big it's biogenpany called reata pharmaceuticals on the sell-side here we're talking about a rare disease, product development, global commercialization they're dealing here with what they call serious neurologic diseases they do have an fda-approved first and only approved treatment for something called freed rick's ataxia in the u.s the premium is quite significant. $172.50. it was trading about $109 yesterday, and the expectation is it will, of course, boost that rare disease portfolio. biogen has been in focus, in part, because of their continued efforts to try to come up with significant advancements in terms of combatting alzheimer's. with some success. previously, not as much. but here, again, $172.50 they've already got the vote, up 36% voting power of certain stock agreements they already have from stockholders there question, of course, in many of these, becomes antitrust you don't expect to see it, but you never know when the amgen horizon, nobody expected the ftc was going to have any iss

what you make of the fda that fully approved biogenic for alzheimer's?his breakthrough treatment? >> a little bittersweet, there is good hope and there are concerns. the good news is it does appear to work, there's a theory if you lower this in the brain it will result in better clinical outcomes, is a theory proven correct. on the downside, there's a black box warning in this new approval today, it warns of severe life-threatening events referring to 13% of patients in the trial that had brain swelling and 19% had a brain bleed. that's about double number of people in the placebo group and three deaths in the group of about 900 so informed consent, only mild and early alzheimer's, pre-alzheimer's like dementia so 75% of people are not even candidates and those of big price tag. liz: 26500 annually so potentially fatal side effects like brain swelling, bleeding, seizures, potentially even death so that's what people need to know first and foremost. this gives hope to all farmers patients, 6.7 million of them out there with their families in but we want t

. -- it is much more connected with biogen -- when it comes to out commerce and dementia.> jimmy, a big we are to you . know what's going on? i need that chill. what's going on? >> listen, everywhere i looked there's a nuclear -- going on worldwide, china 20 new reactors, japan turning on their reactors, becoming a fire train instead of a seller. -- in california got an extension. palisades in michigan need to reopen. -- to invest in the north american -- uranian energy corp . >> i believe, that is much as you tell a positive story about nuclear power, it's still not coming back the way you would like. i actually prefer natural gas to and met -- 50% natural gas, a dollar cost, i like that business. joshua in new jersey, joshua? >> yes, hi jim. i've been reading your book recently . >> i have to rewrite it, i have a new one. what's happening? >> i was just wondering unpowered global management, i cannot figure out if it is the income from the fees . >> that's the problem, the reason why i don't recommend is i don't know how it makes the money, i don't know. i cannot opine v

a drug company, meantime, out east called biogen got fda approval for alzheimer drugs. markets really waiting this morning for news from the labor department and the june jobs report. we've talked about this before, economists seem to always, always underestimate the results. job numbers have been very strong for months and months, much to the chagrin of the fed, which is trying to slow the economy down. bond yields are way up this morning, a sign that both investors expect good job numbers again today and they expect the fed to raise rates again to try to put the brakes on an economic train that just keeps chugging along. >> treasury secretary janet yellen continues her visit to china. she'll meet with central government officials today. yesterday she met with companies in china and was not shy about criticizing chinese officials who interfere with american business in china. >> our economic relationship with china must work for american businesses and american workers. i will always champion your interests and work to make sure there's a level playing field. this incl

when biogen came out with the blockbuster drug what came next was the reality of how expensive it is. about the infusion center, the care, the screening for the test and then the imaging to ensure that the patients are safe along the way. maria: yeah. >> let me start with diagnostics. i did see the segment on the finger prick. i would say there's been tremendous advances. diagnostics will be the game changer many i think you're absolutely right to focus on this topic. the way it works, you have to find

elizabeth: so eli lilly's drug is as effective for women as it is for men, but we talked about how biogen'scing black box warnings about side effects on these drugs. >> well, there is a black box warning on leqembi, there should be one based on the data we with got yesterday on lilly's new drug. it's not that attractive, 24% rate of brain we i deem ma or swelling, a 31% risk of blaine -- brain bleeding. these are not catastrophic or life-threatening bleeds, but a good number of people come off the drug because they cannot tolerate the adverse effects -- events. that's something people are going to have to weigh when they look at the potential benefits and the cost of the drug. elizabeth: what's the cost of the eli lilly drug, do we know? >> it's estimated to come out roughly in the same ballpark as lo lo chem -- leqembi, ab $26,000 per year. it is given about every two weeks as an iv infusion. elizabeth: got it. dr. makary,, really exciting stuff and optimism and e hope for millions of families nationwide. thank you, doctor. >>> we've got this story, is the media finally picking up on alleg

sending strong arrow space demand and record orders you can see shares are up over 6% and finally, biogen is under pressure today as the biotech company slashes around 1,000 jobs to cut costs. this comes as the company rolls out its newly approved but unprofitable alzheimer's drug in the united states. it also reported earnings and revenue, the top estimates but those shares are still down about 3.2% right now brian? >> we just talked about biotech not being able to get out of its own way. there you go kristina partsinevelos, see you in a few minutes >>> we'll take a short break up next, going global. david harrow is here and he's going to break down opportunities he's seeing around the world and what he calls the most undervalued sectors globally this is "closing bell. we're back right after this. >>> welcome back financials are pulling back a little today, although the sector is up over 5% this month, as part of the market's broadening out story your next guest is finding more opportunity outside of the u.s., calling european financials one of the most undervalued sectors. let's bring i

a drug company out east called biogen got fda approval for its alzheimer's drug. it's jobs friday. we just got the latest numbers from the labor department. for the first time in many months, the number came in under estimates. 209,000 jobs added in june. unemployment rate ticks lower to 3.6%. job growth in the past few years has been erratic because of the pandemic. for instance, today's number, 209,000, is the lowest job growth number since december of 2020. but december of 2020's number was negative 200,000. one bit of good news, this may be the soft landing the fed was looking for. >> treasury secretary janet yellen continues her visit to china. she'll meet with government officials today. thursday she met with american companies in china and she was not shy about criticizing chinese officials who interfere with american business in china. >> our economic relationship with china must work for american businesses and american workers. i will always champion your interests and work to make sure there's a level playing field. this includes coordinating with our allies to respond t

ashley: what's biogen doing today? lauren: they have an alzheimer's drug granted full fda approve.o cover much of the $26,5000 cost. the stock is down 1. i'm going to go with buy the rumor, sell the news. ashley: that's expensive, mid goodness. but very encouraging as well. endphase energy, what's about? lauren: the solar stocks are doing welled the to, the president announcing a $600 million -- 60 million investment in enphase and creating 1800 new jobs. ashley: lauren, thank you very much. now this, twitter is considering taking legal action against meta's new social media platform threads. kelly o'grady joins us this morning. how is meta responding to that threat? >> reporter: well, ashley, right now meta shared a a no comment to us when we required about their response, but there are reports of some meta employees claiming on the threads platform that no former twitter employees worked on this project at all. hours after launching day one of threads, the twitter legal team sent a cease and desist letter to ceo mark zuckerberg. they accused threads of stealing twitter's trade se

biogen shares are halted, so, of course, we'll be watching that to see if that's a pop in tomorrow'session tim, where are you in this space, quick >> well, long some lilly, long some pfizer, long some merck this is such exciting news, and clearly an addressable market and excitement around the multiple markets are going to buy first and ask questions later. and ask questions later. >>> up next, final trades. are now for your whole body. plus, fast-working crepe corrector diminishes wrinkled skin in just two days. gold bond. champion your skin. a third kid. what if she likes playing golf? it's expensive. we're outlawing golf. wait. can i still play? since we work with emower, we don't have to worry about planning for a third kid. you can still play golf... sometimes. take control of your financial future to empower what's next. dude, what're you doing? i'm protecting my car. that's too much work. weathertech is so much easier... laser-measured floorliners up here, seat protector and cargoliner back there... nice! out here, side window deflectors... and mud flaps... and the bumpstep, t

. >>> biogen is acquiring reata pharmaceuticals, which is developing therapeutics that regulate cellularshould you be putting your money to work? i want to bring in stephanie link what a week it has been. we thought we might get one of the great streaks of all time. we lost it yesterday afternoon on a relative basis, it's still quite remarkable has the train gone too far or still hasn't left the station? >> i don't think so. i think the economic data that's been coming in is certainly supportive of a soft landing, at least for now. we talk all the time about the consumer the consumer's been resilient because jobs have been so strong wages are up you're seeing autos recover. they're up 16% year over year. housing is back to highs that we saw last year. services are strong. i think pmis have also bottomed. so it's a soft landing we saw that in the gdp yesterday of 2.4%. that's translating into decent earnings 44% of the companies have reported 80% are beating and they're growing earnings overall about 3% people thought we were going to be down about 5 to 10% we have a long way to go, but s

and then don , eisai and biogen and then don, which is the other successful drug, which is by lilly.eague is also a volunteer for donanemab and he's here too. so if you like, he will say a word and tell you what you feel about being on the trial. >> yeah, i'd like to do that. >> yeah, i'd like to do that. >> would definitely like to hear that. always good to hear that. it's always good to hear from people who are actually taking drug . taking this drug. >> hi , can i taking this drug. >> hi, can i can taking this drug. >> hi , can i can see your head >> hi, can i can see your head in a bit. >> i can see you now. so you're taking which drugs are you taking? lee kuan yew nabab as well ? no, no , taking? lee kuan yew nabab as well? no, no , he's taking the well? no, no, he's taking the other one called donelan . other one called donelan. >> donelan. >> donelan. >> de—man . >> de—man. >> de—man. >> yeah. >> yeah. >> none of us can say it. how is it impacted for you? >> been a bit of a problem. that word. >> how has it impacted you then, taking this this drug ? well um, taking this this d

it is made by the japanese pharma company esai and biogen if approved, the second drug in the u.s.26,500 a year joining us now is kavita patel, former obama white house policy director so hard to name drugs that there is a leqembi. we should hear today whether the cms is going to cover this and it looks like it was unanimous fda panel, so it looks like it gets approved and there is some body language that the cms is going to say, okay, we'll cover it. >> cms is earlier already indicated they would put together a coverage program, what we would call coverage with evidence development, essentially asking neurologists and treating physicians to put data elements into a registry to make sure that we're sharing information. by the way, we saw this same sort of requirement with taver, the cardiac procedure. i think cms is trying to send a signal that, yes, indeed, if fda gives it a full approval, it is under accelerated approval now, but with no cms coverage this full cms coverage with conditions signals they will indeed approve this, cover it, both cms and the fda, but the devil is in t